Skip to main content
SpringerLink
Log in

Authors’ Reply to Lambarth: “Levodopa-Carbidopa Intestinal Gel in Patients with Parkinson’s Disease: A Systematic Review”

  • Letter to the Editor
  • Published:
CNS Drugs Aims and scope Submit manuscript

The Original Article was published on 19 August 2016

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Lambarth A. Comment on: “Levodopa-carbidopa intestinal gel in patients with parkinson’s disease: a systematic review”. CNS Drugs. 2016. doi:10.1007/s40263-016-0378-8.

  2. Wirdefeldt K, Odin P, Nyholm D. Levodopa-carbidopa intestinal gel in patients with parkinson’s disease: a systematic review. CNS Drugs. 2016;30(5):381–404.

    Article  CAS  PubMed  Google Scholar 

  3. Olanow CW, Kieburtz K, Odin P, Espay AJ, Standaert DG, Fernandez HH, et al. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson’s disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol. 2014;13(2):141–9.

    Article  CAS  PubMed  Google Scholar 

  4. Nyholm D. Pharmacokinetic optimisation in the treatment of Parkinson’s disease: an update. Clin Pharmacokinet. 2006;45(2):109–36.

    Article  CAS  PubMed  Google Scholar 

  5. Devos D, French DSG. Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson’s disease. Mov Disord. 2009;24(7):993–1000.

    Article  PubMed  Google Scholar 

  6. Antonini A, Yegin A, Preda C, Bergmann L, Poewe W, Gloria study investigators and coordinators. Global long-term study on motor and non-motor symptoms and safety of levodopa-carbidopa intestinal gel in routine care of advanced Parkinson’s disease patients: 12-month interim outcomes. Parkinsonism Relat Disord. 2015;21(3):231–5.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Solna, Sweden

    Karin Wirdefeldt

  2. Department of Clinical Neuroscience, Karolinska Institutet, Solna, Sweden

    Karin Wirdefeldt

  3. Department of Neurology, Skåne University Hospital, Lund, Sweden

    Per Odin

  4. Klinikum-Bremerhaven, Bremerhaven, Germany

    Per Odin

  5. Department of Neuroscience, Neurology, Uppsala University, Akademiska sjukhuset, 75185, Uppsala, Sweden

    Dag Nyholm

Authors
  1. Karin Wirdefeldt
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Per Odin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dag Nyholm
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dag Nyholm.

Ethics declarations

Funding

No funding has been received for the preparation of this reply.

Conflict of interest

Karin Wirdefeldt has no conflicts of interest.

Per Odin has received payment for lectures and expert consultations from AbbVie, Britannia, NordicInfu Care, UCB and Zambon.

Dag Nyholm receives royalties from Liber AB; has served as a consultant to Sensidose AB and OrbiMed Advisors LLC; has received honoraria from H. Lundbeck AB, Movement Disorders Society, NordicInfu Care, and The National Board of Health and Welfare; has received lecture fees from AbbVie and NordicInfu Care; has received research support from AbbVie, Ipsen, Selanders Foundation, Swedish Knowledge Foundation, Swedish Parkinson’s Disease Foundation, Swedish Research Council, and VINNOVA, Sweden’s innovation agency; is a co-founder and stock owner in Jemardator AB; receives remuneration from the website netdoktor.se for participation in an expert panel; and has received institutional support from Uppsala University Hospital.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wirdefeldt, K., Odin, P. & Nyholm, D. Authors’ Reply to Lambarth: “Levodopa-Carbidopa Intestinal Gel in Patients with Parkinson’s Disease: A Systematic Review”. CNS Drugs 30, 1009–1010 (2016). https://doi.org/10.1007/s40263-016-0379-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40263-016-0379-7

Keywords

Search

Navigation